5-(2-hydroxyethyl)-3-(hydroxymethyl)-2,4,6-trimethyl-1H-inden-7-ol | 247256-81-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚和异茚
• 英文名称: 5-(2-hydroxyethyl)-3-(hydroxymethyl)-2,4,6-trimethyl-1H-inden-7-ol
• 英文别名: 1H-Indene-5-ethanol, 7-hydroxy-3-(hydroxymethyl)-2,4,6-trimethyl-；6-(2-hydroxyethyl)-1-(hydroxymethyl)-2,5,7-trimethyl-3H-inden-4-ol
• CAS: 247256-81-1
• 化学式: C₁₅H₂₀O₃
• 分子量: 248.322
• InChiKey: ONDIIKFGSWRMSU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  60.7
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  (-)-伊洛福芬 在 硫酸 、 锌 作用下， 以 丙酮 为溶剂， 反应 0.5h， 以680 mg的产率得到6-(2-hydroxyethyl)-2,5,7-trimethyl-1-methylene-1H-inden-4-ol
  参考文献：
  名称：

  伊洛富尔芬与锌和酸的反应。

  摘要：

  抗肿瘤药伊洛富尔芬（Irofulven）（1）与锌和乙酸反应生成了几种新的茚衍生物（6、7、8、10）和已知的茚（9）。与伊洛夫芬相比，所有这些都大大降低了对人白血病（HL60）细胞的毒性。

  DOI：

  10.1021/np0204085

文献信息

• METHODS, COMPOSITIONS AND DEVICES FOR TREATING CANCER WITH ILLUDOFULVENES
  申请人：Kelner, Michael

  公开号：EP3667323A1

  公开（公告）日：2020-06-17

  The present invention relates to compositions, methods and devices for treating cancer with illudofulvenes including methods to detect the expression levels of genes encoding biomarkers in cancer patients and to predict the responsiveness of cancer patients to illudofulvenes.

  本发明涉及用紫杉醇治疗癌症的组合物、方法和装置，包括检测癌症患者体内编码生物标志物的基因表达水平和预测癌症患者对紫杉醇反应性的方法。
• Affinity medicant conjugates
  申请人：AF Chemicals, LLC

  公开号：US11135182B2

  公开（公告）日：2021-10-05

  In an embodiment of the invention, a composition for treating a cell population comprises an Affinity Medicant Conjugate (AMC). The medicant moiety can be a toxin including an acylfulvene or a drug moiety. The affinity moiety can be an antibody, a binding protein, a steroid, a lipid, a growth factor, a protein, a peptide or non peptidic. The affinity moiety can be covalently bound to the medicant via a linker. Novel linkers that can be directed to cysteine, arginine or lysine residues based on solution pH allow greater flexibility in preserving and/or generating specific epitopes in the AMC.

  在本发明的一个实施方案中，一种用于治疗细胞群的组合物包含一种亲和药剂共轭物（AMC）。药剂分子可以是包括酰化芬在内的毒素或药物分子。亲和剂可以是抗体、结合蛋白、类固醇、脂质、生长因子、蛋白质、肽或非肽。亲和分子可以通过连接体与药物共价结合。新型连接体可根据溶液 pH 值定向连接半胱氨酸、精氨酸或赖氨酸残基，从而更灵活地保留和/或生成 AMC 中的特定表位。
• Affinity medicant conjugate
  申请人：Califia Pharma Inc.

  公开号：US11241398B2

  公开（公告）日：2022-02-08

  In an embodiment of the invention, a composition for treating a cell population comprises an Affinity Medicant Conjugate (AMC). The medicant moiety can be a toxin including an acylfulvene or a drug moiety. The affinity moiety can be an antibody, a binding protein, a steroid, a lipid, a growth factor, a protein, a peptide or non peptidic. The affinity moiety can be covalently bound to the medicant via a linker. Novel linkers that can be directed to cysteine, arginine or lysine residues based on solution pH allow greater flexibility in preserving and/or generating specific epitopes in the AMC.

  在本发明的一个实施方案中，一种用于治疗细胞群的组合物包含一种亲和药剂共轭物（AMC）。药剂分子可以是包括酰化芬在内的毒素或药物分子。亲和剂可以是抗体、结合蛋白、类固醇、脂质、生长因子、蛋白质、肽或非肽。亲和分子可以通过连接体与药物共价结合。新型连接体可根据溶液 pH 值定向连接半胱氨酸、精氨酸或赖氨酸残基，从而更灵活地保留和/或生成 AMC 中的特定表位。
• AFFINITY MEDICANT CONJUGATE
  申请人：AF CHEMICALS, LLC

  公开号：US20150290152A1

  公开（公告）日：2015-10-15

  In an embodiment of the invention, a composition for treating a cell population comprises an Affinity Medicant Conjugate (AMC). The medicant moiety can be a toxin including an acylfulvene or a drug moiety. The affinity moiety can be an antibody, a binding protein, a steroid, a lipid, a growth factor, a protein, a peptide or non peptidic. The affinity moiety can be covalently bound to the medicant via a linker. Novel linkers that can be directed to cysteine, arginine or lysine residues based on solution pH allow greater flexibility in preserving and/or generating specific epitopes in the AMC.
• US7718385B2
  申请人：——

  公开号：US7718385B2

  公开（公告）日：2010-05-18